Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma

IMPORTANCE: Clinical trials have shown an overall survival (OS) benefit associated with first-line immunotherapy (IT) and combination targeted therapy (TT) and IT regimens compared with TT among patients with metastatic clear cell renal cell carcinoma (RCC). Generalizability of these findings in a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakiryan, Nicholas H., Jiang, Da David, Gillis, Kyle A., Green, Elizabeth, Hajiran, Ali, Hugar, Lee, Zemp, Logan, Zhang, Jingsong, Jain, Rohit K., Chahoud, Jad, Spiess, Philippe E., Sexton, Wade, Gilbert, Scott M., Manley, Brandon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150693/
https://www.ncbi.nlm.nih.gov/pubmed/34032854
http://dx.doi.org/10.1001/jamanetworkopen.2021.11329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150693/
https://www.ncbi.nlm.nih.gov/pubmed/34032854
http://dx.doi.org/10.1001/jamanetworkopen.2021.11329

Ejemplares similares